Rebecca Omalley, MD
Urology · Albany, NYNPI 1053501114
Payments from drug & device makers
Across 47 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$186
- AbbVie$172
- Ferring Pharmaceuticals Inc.$163
- Antares Pharma, Inc.$134
- Sumitomo Pharma America, Inc.$81
- Merck$75
- plus $390 from 13 others
What the payments were for
- Food & beverage$1,203100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 4 | $186 |
| AbbVie | 8 | $172 |
| Ferring Pharmaceuticals Inc. | 5 | $163 |
| Antares Pharma, Inc. | 6 | $134 |
| Sumitomo Pharma America, Inc. | 3 | $81 |
| Merck | 3 | $75 |
| Boston Scientific | 2 | $69 |
| Endo Pharmaceuticals Inc. | 2 | $47 |
| Halozyme Inc | 2 | $46 |
| 180 Medical, Inc. | 2 | $42 |
| Tolmar, Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $26 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Axonics, Inc. | 1 | $18 |
| Coloplast | 1 | $18 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Dentsply IH AB | 1 | $16 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$123
How this compares
$1,203 in reported general payments places this provider in the 35th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 93 | $1,146 |
| Finasteride | 60 | $751 |
| Oxybutynin Chloride ErOxybutynin Chloride | 28 | $538 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $289 |
| Ciprofloxacin Hcl | 27 | $204 |
| CefuroximeCefuroxime Axetil | 12 | $140 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $79 |
Paid to pharmacies, not to this prescriber.
Other urology in Albany
- Badar MianAlbany$1.1M
- Ronald KaufmanAlbany$421K
- Christopher PieczonkaSyracuse$31.2M
- Guarionex DecastroNew York$5.7M
- Mitchell EfrosGarden City$4.2M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Jed KaminetskyMiddle Village$3.5M
- Evan GoldfischerPoughkeepsie$3.1M
- Gennady BratslavskySyracuse$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.